Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794716 | 0.90 | SYK (1.00) | SYKZAP70KCNH2AURKB | |
| SCHEMBL2383949 | 0.90 | SYK (1.00) | SYKZAP70KCNH2AURKB | |
| SCHEMBL4716047 | 0.89 | SYK (1.00) | SYKZAP70KCNH2AURKB | |
| SCHEMBL1354433 | 0.82 | SYK (0.86) | SYKZAP70KCNH2AURKB | |
| SCHEMBL13733951 | 0.82 | SYK (0.69) | SYKZAP70KCNH2AURKB | |
| SCHEMBL4714843 | 0.81 | SYK (0.78) | SYKZAP70KCNH2AURKB | |
| SCHEMBL1352244 | 0.81 | SYK (0.83) | SYK | |
| SCHEMBL4712719 | 0.81 | SYK (0.77) | SYKZAP70KCNH2AURKB | |
| SCHEMBL1352241 | 0.81 | SYK (0.83) | SYK | |
| SCHEMBL29794597 | 0.81 | SYK (0.77) | SYKZAP70KCNH2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013155381-A1 | TREATMENT FOR MICROBE-INDUCED INFLAMMATORY RESPONSES IN THE EYE | ALCON RESEARCH, LTD. (US) | 2013-10-17 | — | — | WO | claimed |
| EP-1054004-B1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | EP | claimed |
| US-20080139531-A1 | USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR | ALCON MANUFACTURING LTD. (US) | 2008-06-12 | — | — | US | claimed |
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | NYCOMED GMBH (DE) | 2008-01-31 | — | — | US | claimed |
| EP-1796679-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | claimed |
| EP-1791538-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027378-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| WO-2006027377-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| US-6432963-B1 | ANTIINFLAMMATORY AGENTS; TYROSINE KINASE INHIBITOR | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | claimed |
| EP-1054004-A1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-11-22 | — | — | EP | claimed |
| CN-114945378-B | Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells and related uses thereof | 休斯敦大学体系 | 2024-11-19 | — | — | CN | disclosed |
| US-20240158756-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-16 | — | — | US | disclosed |
| US-11779634-B2 | Fungal iron acquisition inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| CN-114945378-A | Feeder-layer and feeder-layer-free stem cell culture systems for stratified epithelial stem cells and uses related thereto | 休斯敦大学体系 | 2022-08-26 | — | — | CN | disclosed |
| EP-4041259-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-1791538-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027378-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027377-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
| US-6432963-B1 | ANTIINFLAMMATORY AGENTS; TYROSINE KINASE INHIBITOR | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1054004-A1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | SYK, ZAP70, BTK | SYK 1/4885ZAP70 2/4885KCNH2 4123/4885 |
| US-20080139531-A1 | USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR | CMA1, LTK, KIT | SYK 17/4885ZAP70 11/4885KCNH2 1134/4885 |
| US-11779634-B2 | Fungal iron acquisition inhibitors and uses thereof | SLC40A1, SLC30A6, SLC30A7 | SYK 1939/4885ZAP70 1432/4885KCNH2 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.